James Ninia, MD

home / authors / james-ninia-md

Articles

James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.

Ongoing Consolidative RT Trial May Support Efficacy Findings in SCLC

James Ninia, MD
October 9th 2024

James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.

Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.

PFS Benefit Occurs with Complete vs Incomplete Consolidative RT in ES-SCLC

James Ninia, MD
October 8th 2024

Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.

James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.

Assessing Consolidative Radiation in Extensive-Stage Small Cell Lung Cancer

James Ninia, MD
October 8th 2024

James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
TAS-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.
Published: October 9th 2024 | Updated: October 15th 2024
TAR-200 Study in Muscle-Invasive Bladder Cancer Discontinued
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care
Published: September 24th 2024 | Updated: October 15th 2024
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility
Published: September 23rd 2024 | Updated: October 15th 2024
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility